Date: 2015-04-22
Type of information: Production agreement
Compound: HIV-antigen plasmid DNA
Company: Vical (USA - CA) IPPOX Foundation (Switzerland)
Therapeutic area: Infectious diseases
Type agreement: production manufacturing
Action mechanism:
Disease: HIV - AIDS
Details: * On April 22, 2015, Vical announced that it has entered into a $4 million contract with the IPPOX Foundation to manufacture HIV-antigen plasmid DNA as a component of vaccine regimens to be evaluated in clinical trials for the prevention of HIV infection. IPPOX is a Swiss non-profit foundation that participates in the conduct of HIV vaccine clinical trials under the auspices of the Pox-Protein Public-Private Partnership (P5), funded by the Bill & Melinda Gates Foundation and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The new contract builds upon Vical\'s 2010 agreement with IPPOX to manufacture plasmid DNA for HIV vaccine clinical trials and recent encouraging clinical data. The plasmids manufactured by Vical are expected to be used as priming components of prime/boost vaccine regimens that will be evaluated in additional Phase 1 studies and potentially in a Phase 2b clinical trial to follow. Vical expects material delivery to begin in the fourth quarter of 2015. Additionally, Vical has signed a Memorandum of Understanding with the Gates Foundation to cooperate on HIV vaccine projects established under the P5 partnership. P5 seeks to advance and potentially license HIV vaccine candidates that have the potential to achieve a broad public health impact. Core funding for P5 is provided by the foundation and the NIH, and current partners include the foundation, U.S. National Institute of Allergy and Infectious Diseases/Division of AIDS, the HIV Vaccine Trials Network, Novartis Vaccines and Diagnostics, Sanofi Pasteur, the South Africa Medical Research Council, the U.S. Military HIV Research Program (MHRP), GSK, and Centre Hospitalier Universitaire Vaudois (CHUV).
Financial terms:
Latest news:
